title: Utility of physiologically based modeling and preclinical in vitro/in vivo data to mitigate positive food effect in a BCS class 2 compound.
abstract: Physiologically based pharmacokinetic (PBPK) modeling has become a useful tool to estimate the performance of orally administrated drugs. Here, we described multiple in silico/in vitro/in vivo tools to support formulation development toward mitigating the positive food effect of NVS123, a weak base with a pH-dependent and limited solubility. Administered orally with high-fat meal, NVS123 formulated as dry filled capsules displayed a positive food effects in humans. Three alternative formulations were developed and assessed in in vitro and in vivo preclinical and/or clinical studies. By integrating preclinical in vitro and in vivo data, the PBPK model successfully estimated the magnitude of food effects and the predicted values were within ± 30% of the observed results. A model-guided parameter sensitivity analysis illustrated that enhanced solubility and longer precipitation times under fed condition were the main reason for enhanced NVS123's exposure in presence of food. Eventually, exposure after an amorphous formulation was found to be not significantly altered because of remarkably enhanced intestinal solubility and reduced precipitation. Gastroplus population simulations also suggested that the amorphous formulation is promising in mitigating a clinically significant food effect. Overall, these efforts supported the rationale of clinical investigation of the new formulation, and more importantly, highlighted a practical application of PBPK modeling solving issues of undesirable food effects in weakly basic compounds based on preclinical in vitro/in vivo data.
authors: Department Drug Metabolism and Pharmacokinetics, Novartis Institute for Biomedical Research, One Health Plaza 436 3253, East Hanover, New Jersey 07936, USA.
authors: Binfeng
authors: B
authors: Xia
authors: Tycho
authors: T
authors: Heimbach
authors: Tsu-han
authors: TH
authors: Lin
authors: Shoufeng
authors: S
authors: Li
authors: Hefei
authors: H
authors: Zhang
authors: Jennifer
authors: J
authors: Sheng
authors: Handan
authors: H
authors: He
mesh_terms: D000284:Administration, Oral; D000818:Animals; D018592:Cross-Over Studies; D004285:Dogs; D018565:Food-Drug Interactions; D006801:Humans; D066298:In Vitro Techniques; D008954:Models, Biological; D010599:Pharmacokinetics; D012995:Solubility
references: AAPS J. 2011 Mar;13(1):59-71
references: 21207216
references: Clin Pharmacokinet. 1999 Mar;36(3):233-54
references: 10223170
references: J Pharm Sci. 1999 Jul;88(7):731-8
references: 10393573
references: J Pharm Sci. 2007 Feb;96(2):459-72
references: 17075867
references: J Pharm Pharmacol. 1972 Dec;24(12):979-81
references: 4146531
references: J Appl Physiol (1985). 2002 Feb;92(2):427-34
references: 11796648
references: AAPS J. 2008 Jun;10(2):282-8
references: 18500565
references: AAPS J. 2009 Mar;11(1):45-53
references: 19184451
references: Eur J Pharm Biopharm. 2000 Mar;49(2):99-102
references: 10704891
references: J Pharm Sci. 1986 Mar;75(3):271-4
references: 3701609
references: AAPS J. 2013 Jan;15(1):143-58
references: 23139017
references: Clin Pharmacokinet. 2006;45(12):1213-26
references: 17112297
references: Pharm Res. 1996 Jan;13(1):163-7
references: 8668668
references: Gastroenterology. 1985 Oct;89(4):805-13
references: 4029560
references: Adv Drug Deliv Rev. 2008 Mar 17;60(6):717-33
references: 18199522
references: Pharm Res. 2005 Jan;22(1):11-23
references: 15771225